
Nexxen Launches Health Offering to Reach Key Audiences with Accuracy and Scale
Data-driven, end-to-end platform enables marketing strategies that ensure compliance while maximizing impact across display, linear & Connected TV
Innovative integration with leading healthcare analytics company PurpleLab provides powerful audience-building and reporting tools
NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Nexxen (NASDAQ: NEXN), a global, flexible advertising platform with deep expertise in data and advanced TV, today announced the launch of Nexxen Health, a new offering enabling health advertisers to run data-driven advertising campaigns that efficiently reach audiences and maximize impact across traditional and emerging formats, including display, linear and Connected TV ('CTV'), while maintaining privacy compliance.
A strategic component of the offering – an innovative integration between Nexxen's proprietary audience discovery tool and PurpleLab ®, a healthcare analytics company that holds the largest medical and pharmaceutical claims database in the US – can add additional layers of accuracy to pharmaceutical advertising campaigns while also extending reach with new patient and healthcare provider audiences.
'In a fast-changing, fragmented advertising and regulatory landscape, it's critical for health and pharmaceutical brands to leverage flexible technology and powerful data that keeps them agile, precise and ready to capitalize on the opportunities emerging across display, CTV and linear,' said Chance Johnson, Chief Commercial Officer, Nexxen. 'Nexxen simplifies healthcare advertising by offering scalable, high-quality video inventory alongside unique medical and pharmaceutical data solutions. Our approach enables precise audience discovery while maintaining compliance, supported by advanced planning tools, for measurable results.'
'We applaud Nexxen's ongoing commitment to developing innovative, new ways to enhance campaign reach, optimization and measurement in the healthcare space,' said Kristy Quagliariello, Vice President, Programmatic Media, Klick Health. 'We have been using Nexxen Discovery to yield critical insights for our growing roster of life sciences clients and are energized by how its integration of PurpleLab's data promises to add a layer of qualification to our audiences prior to activation, and generate added levels of accuracy and insights for our clients.'
Nexxen's integrated DSP and SSP offer health and pharmaceutical brands a direct path to premium, omnichannel inventory, driving efficiencies by maximizing match rates, reducing data loss and enabling real-time measurement, with real-time optimization to come in 2025. The platform's audience discovery tool, Nexxen Discovery, optimizes audience quality through contextual refinement, while Nexxen TV Audiences, a dataset incorporating Nexxen's unique automatic content recognition ('ACR') data, enables coordination of health and pharmaceutical campaign reach across linear and digital.
Augmenting the power of Nexxen Discovery is a partnership with PurpleLab that integrates healthcare data from the country's largest healthcare claims database with Nexxen's contextual targeting capabilities. Through this partnership, Nexxen Discovery users will have the ability to activate and measure outcomes on approximately 500 privacy-safe and contextually relevant, direct-to-consumer healthcare audiences programmatically.
ABOUT NEXXEN
Nexxen empowers advertisers, agencies, publishers and broadcasters around the world to utilize data and advanced TV in the ways that are most meaningful to them. Our flexible and unified technology stack comprises a demand-side platform ('DSP') and supply-side platform ('SSP'), with the Nexxen Data Platform at its core. With streaming in our DNA, Nexxen's robust capabilities span discovery, planning, activation, monetization, measurement and optimization – available individually or in combination – all designed to enable our partners to achieve their goals, no matter how far-reaching or hyper niche they may be.
Nexxen is headquartered in Israel and maintains offices throughout the United States, Canada, Europe and Asia-Pacific, and is traded on the Nasdaq (NEXN). For more information, visit www.nexxen.com
For more information, please contact:
Caroline Smith
Vice President, Communications, Nexxen
Forward Looking Statement
This press release contains forward-looking statements, including forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities and Exchange Act of 1934, as amended. Forward-looking statements are identified by words such as 'anticipates,' 'believes,' 'expects,' 'intends,' 'may,' 'can,' 'will,' 'estimates,' and other similar expressions. However, these words are not the only way Nexxen identifies forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the launch of Nexxen's health offering and any benefits or insights associated with the solutions as well as any benefits associated with any of Nexxen's products and platforms including the Nexxen Marketplaces, Discovery Tool, cross-screen measurement tools, Data Platform and CTV offering. These statements are neither promises nor guarantees but involve known and unknown risks, uncertainties and other important factors that may cause Nexxen's actual results, performance or achievements to be materially different from its expectations expressed or implied by the forward-looking statements, including, but not limited to, the following: negative global economic conditions; global conflicts and war, including the current terrorist attacks by Hamas, and the war and hostilities between Israel and Hamas and Israel and Hezbollah, and how those conditions may adversely impact Nexxen's business, customers, and the markets in which Nexxen competes. Nexxen cautions you not to place undue reliance on these forward-looking statements. For a more detailed discussion of these factors, and other factors that could cause actual results to vary materially, interested parties should review the risk factors listed in the Company's most recent Annual Report on Form 20-F, filed with the U.S. Securities and Exchange Commission (www.sec.gov) on March 5, 2025. Any forward-looking statements made by Nexxen in this press release speak only as of the date of this press release, and Nexxen does not intend to update these forward-looking statements after the date of this press release, except as required by law.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Is Broadcom Stock Your Ticket to Becoming a Millionaire?
Artificial intelligence (AI) is moving the needle significantly for Broadcom, and that trend could continue thanks to the huge addressable market it is serving. The chipmaker is now expected to clock stronger growth in the coming years thanks to AI. Broadcom's impressive growth and valuation make the stock an attractive buy. 10 stocks we like better than Broadcom › The artificial intelligence (AI) boom has supercharged Broadcom's (NASDAQ: AVGO) growth in recent quarters, with the company now getting a significant chunk of its revenue from selling custom processors and networking chips deployed by major cloud service providers in their data centers. The stock has made a big move in the past couple of months, jumping an impressive 41% as of this writing and going well past $1 trillion in market cap. The good part is that Broadcom is scratching the surface of a massive opportunity in the AI chip market that could help it sustain solid growth rates for a long time to come. Of course, buying just Broadcom and hoping that it will help you become a millionaire isn't a smart thing to do, as any cracks in the company's growth story could send the stock plunging. However, Broadcom looks like an ideal pick for investors aiming to construct a diversified million-dollar portfolio. Let's look at the reasons why. Broadcom released its fiscal 2025 second-quarter results (for the three months ended May 4) on June 5. Its revenue jumped 20% year over year to $15 billion, while adjusted earnings shot up at a stronger pace of 43%. AI played a key role in driving this robust growth. The company's AI revenue jumped 46% year over year to $4.4 billion, which means it's now getting almost 30% of its top line by supplying chips powering this technology. What's worth noting here is that Broadcom is anticipating further acceleration in its AI revenue in the current quarter, projecting $5.1 billion in revenue. That would be an improvement of 60% from the year-ago period. What's more, Broadcom CEO Hock Tan indicated on the latest earnings conference call that the company's AI revenue growth trajectory is sustainable. Tan remarked that the growth rate Broadcom is witnessing so far in fiscal 2025 "will presumably continue." That's not surprising, considering that Broadcom is now seeing stronger demand for its custom AI chips (known as XPUs) for inference purposes. Management says that the three existing customers who are deploying its custom chips in data centers for AI training remain firm in their infrastructure investment plans, despite the economic uncertainty created by the tariff war. At the same time, those three customers "are doubling down on inference in order to monetize their platforms," which is why the company anticipates "an acceleration of XPU demand into the back half of 2026 to meet urgent demand for inference on top of the demand we have indicated from training." A big reason why Broadcom should be able to sustain its impressive AI revenue growth rate is because of the massive addressable opportunity worth $60 billion to $90 billion that it sees for its AI chips by fiscal 2027 based on the three customers it's currently serving. Given that the company has generated $13.6 billion in revenue from sales of its AI chips in the first three quarters of the year, it still has a lot of room to grow in this market. That's especially true considering that another four hyperscalers are in negotiations with Broadcom for manufacturing custom AI processors. As a result, Broadcom may be sitting on a much larger AI-related addressable market, which explains why analysts have raised their growth expectations for the company following its latest results. Broadcom is trading at just under 38 times forward earnings as of this writing following its recent surge. While that may seem expensive at first, we have seen that the company's outstanding earnings growth justifies its rich valuation. Another important thing worth noting is that Broadcom's price/earnings-to-growth ratio (PEG ratio) based on its projected earnings growth for the next five years stands at just 0.66, according to Yahoo! Finance. The PEG ratio is a forward-looking valuation metric calculated by dividing a company's price-to-earnings ratio by its estimated annual earnings growth rate for the next five years. A reading of less than 1 means that the stock in question is undervalued, and Broadcom's multiple is well below that mark. All this makes Broadcom a solid growth stock to buy right now, since it seems built for terrific long-term upside and has the potential to contribute positively toward a million-dollar portfolio. Before you buy stock in Broadcom, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Broadcom wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $655,255!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $888,780!* Now, it's worth noting Stock Advisor's total average return is 999% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Harsh Chauhan has no position in any of the stocks mentioned. The Motley Fool recommends Broadcom. The Motley Fool has a disclosure policy. Is Broadcom Stock Your Ticket to Becoming a Millionaire? was originally published by The Motley Fool Se produjo un error al recuperar la información Inicia sesión para acceder a tu portafolio Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información
Yahoo
3 hours ago
- Yahoo
Why Tesla Stock Soared This Week
Tesla CEO Elon Musk apologized for some of his comments last week that have weakened his relationship with the White House, boosting the stock. However, the reported launch of Tesla robotaxis in Austin, Texas, has been delayed to later this month. The company's declining sales are a major concern. These 10 stocks could mint the next wave of millionaires › Shares of Tesla (NASDAQ: TSLA) are up this week, climbing 10.3% as of market close on Friday. The rise came as the S&P 500 (SNPINDEX: ^GSPC) and the Nasdaq Composite (NASDAQINDEX: ^IXIC) both sank modestly. Tesla stock recovered this week after the public spat between CEO Elon Musk and President Trump cooled. Last week, Musk and Trump found themselves in a very public spat. What began as criticism of Trump's flagship "Big, Beautiful Bill" escalated into personal attacks and serious accusations. Musk deleted his most incendiary post and apologized on X, saying that some of his posts last week had gone "too far." The de-escalation of the situation sent Tesla stock higher. The stock was also on the rise this week in anticipation of Tesla's reported robotaxi launch. According to a report from Bloomberg, Tesla was set to begin operating its vehicles autonomously in Austin, Texas, on June 12. However, it's now clear that the company has pushed back this date, now targeting June 22. Despite the delay, Tesla shares were up further on Friday. This is not the first time the company has failed to meet a target launch date or milestone for its autonomous driving technology. Musk previously said he was "very confident predicting" that there would be 1 million of his robotaxis on the roads no later than "next year" -- in 2019. I am dubious of the company's ability to deliver on its promises, and given the state of its current vehicle sales (which are seeing massive declines), I think this stock is extremely overvalued. Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $376,048!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $37,816!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $655,255!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of June 9, 2025 Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tesla. The Motley Fool has a disclosure policy. Why Tesla Stock Soared This Week was originally published by The Motley Fool
Yahoo
3 hours ago
- Yahoo
MGP Ingredients (NASDAQ:MGPI) investors are sitting on a loss of 68% if they invested three years ago
The truth is that if you invest for long enough, you're going to end up with some losing stocks. Long term MGP Ingredients, Inc. (NASDAQ:MGPI) shareholders know that all too well, since the share price is down considerably over three years. Unfortunately, they have held through a 69% decline in the share price in that time. And more recent buyers are having a tough time too, with a drop of 61% in the last year. More recently, the share price has dropped a further 10% in a month. So let's have a look and see if the longer term performance of the company has been in line with the underlying business' progress. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). MGP Ingredients saw its EPS decline at a compound rate of 54% per year, over the last three years. This fall in the EPS is worse than the 32% compound annual share price fall. So the market may not be too worried about the EPS figure, at the moment -- or it may have previously priced some of the drop in. This positive sentiment is also reflected in the generous P/E ratio of 57.06. The image below shows how EPS has tracked over time (if you click on the image you can see greater detail). It's good to see that there was some significant insider buying in the last three months. That's a positive. That said, we think earnings and revenue growth trends are even more important factors to consider. It might be well worthwhile taking a look at our free report on MGP Ingredients' earnings, revenue and cash flow. MGP Ingredients shareholders are down 60% for the year (even including dividends), but the market itself is up 12%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 3% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 4 warning signs for MGP Ingredients you should be aware of. MGP Ingredients is not the only stock insiders are buying. So take a peek at this free list of small cap companies at attractive valuations which insiders have been buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données